<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36709083</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4981</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Trends in immunology</Title><ISOAbbreviation>Trends Immunol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccines and a perspective on Africa.</ArticleTitle><Pagination><StartPage>172</StartPage><EndPage>187</EndPage><MedlinePgn>172-187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.it.2023.01.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1471-4906(23)00005-4</ELocationID><Abstract><AbstractText>Vaccines have dramatically changed the COVID-19 pandemic. Over 30 vaccines that were developed on four main platforms are currently being used globally, but a deep dissection of the immunological mechanisms by which they operate is limited to only a few of them. Here, we review the evidence describing specific aspects of the modes of action of COVID-19 vaccines; these include innate immunity, trained innate immunity, and mucosal responses. We also discuss the use of COVID-19 vaccines in the African continent which is ridden with inequality in its access to vaccines and vaccine-related immunological research. We argue that strengthening immunology research in Africa should inform on fundamental aspects of vaccination, including the relevance of genetics, trained innate immunity, and microbiome diversity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mantovani</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy; William Harvey Research Institute, Queen Mary University, London EC1M 6BQ, UK. Electronic address: alberto.mantovani@humanitasresearch.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rescigno</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forni</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Accademia Nazionale dei Lincei, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tognon</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Operational Research Unit, Doctors with Africa CUAMM, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putoto</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Head of Planning and Operational Research, Doctors with Africa CUAMM, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ictho</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology, Doctors with Africa CUAMM, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lochoro</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Health Service Management, Doctors with Africa CUAMM, Uganda. Electronic address: p.lochoro@cuamm.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Immunol</MedlineTA><NlmUniqueID>100966032</NlmUniqueID><ISSNLinking>1471-4906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Africa</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">immune imprinting</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">mucosal responses</Keyword><Keyword MajorTopicYN="N">trained immunity</Keyword><Keyword MajorTopicYN="N">vaccine inequality</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>Declaration of interests No interests are declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>28</Day><Hour>21</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36709083</ArticleId><ArticleId IdType="pmc">PMC9832054</ArticleId><ArticleId IdType="doi">10.1016/j.it.2023.01.005</ArticleId><ArticleId IdType="pii">S1471-4906(23)00005-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Msemburi W., et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613:130&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812776</ArticleId><ArticleId IdType="pubmed">36517599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., et al. Long COVID: where we stand and challenges ahead. Cell Death Differ. 2022;29:1891&#x2013;1900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs J.D., et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet. 2022;400:1224&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539542</ArticleId><ArticleId IdType="pubmed">36115368</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva T.M.R., et al. Number of doses of measles-mumps-rubella vaccine applied in Brazil before and during the COVID-19 pandemic. BMC Infect. Dis. 2021;21:1237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8655492</ArticleId><ArticleId IdType="pubmed">34886804</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O.J., et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 2022;22:1293&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Usher A.D. A beautiful idea: how COVAX has fallen short. Lancet. 2021;397:2322&#x2013;2325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494620</ArticleId><ArticleId IdType="pubmed">34147145</ArticleId></ArticleIdList></Reference><Reference><Citation>Accademia Nazionale dei Lincei . Summer 2022. Accademia Nazionale dei Lincei; 2022. Report on COVID-19 Vaccines.https://www.lincei.it/sites/default/files/documenti/Commissioni/ANL_Com-Covid_DOC_vaccini_20220708.pdf</Citation></Reference><Reference><Citation>Topol E.J. Messenger RNA vaccines against SARS-CoV-2. Cell. 2021;184:1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7805392</ArticleId><ArticleId IdType="pubmed">33740443</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary N., et al. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 2021;20:817&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386155</ArticleId><ArticleId IdType="pubmed">34433919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendon&#xe7;a S.A., et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vacc. 2021;6:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342436</ArticleId><ArticleId IdType="pubmed">34354082</ArticleId></ArticleIdList></Reference><Reference><Citation>Forni G., et al. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28:626&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818063</ArticleId><ArticleId IdType="pubmed">33479399</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H. Covid-19 vaccines &#x2013; immunity, variants, boosters. N. Engl. J. Med. 2022;387:1011&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., et al. Immune response in COVID-19: what is next? Cell Death Differ. 2022;29:1107&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110941</ArticleId><ArticleId IdType="pubmed">35581387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Anon Africa is bringing vaccine production home. Nature. 2022;602:184.</Citation><ArticleIdList><ArticleId IdType="pubmed">35140392</ArticleId></ArticleIdList></Reference><Reference><Citation>GAVI . GAVI; 2022. Expanding Sustainable Vaccine Manufacturing in Africa: Priorities for Support.www.gavi.org/sites/default/files/document/2022/Gavi-Expanding-Sustainable-Vaccine-Manufacturing-in-Africa-2022.pdf</Citation></Reference><Reference><Citation>Kariko K., et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008;16:1833&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775451</ArticleId><ArticleId IdType="pubmed">18797453</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan G., et al. A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates. Sci. Rep. 2016;6:34215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050434</ArticleId><ArticleId IdType="pubmed">27703172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 2018;215:1571&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5987916</ArticleId><ArticleId IdType="pubmed">29739835</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh M.G., et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877&#x2013;2892 e2877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566475</ArticleId><ArticleId IdType="pubmed">34852217</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 2022;23:543&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989677</ArticleId><ArticleId IdType="pubmed">35288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahtinen S., et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 2022;23:532&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">35332327</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke R., et al. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55:1993&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9641982</ArticleId><ArticleId IdType="pubmed">36351374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen S., et al. Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses. PLoS Pathog. 2022;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812972</ArticleId><ArticleId IdType="pubmed">35073387</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang F., et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 2017;25:2635&#x2013;2647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5768558</ArticleId><ArticleId IdType="pubmed">28958578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen S., et al. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604799</ArticleId><ArticleId IdType="pubmed">34841223</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596:410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonez C., et al. Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways. Nanomedicine. 2014;10:775&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">24361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao L., et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 2019;37:1174&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">31570898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., et al. DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur. J. Immunol. 2008;38:1351&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">18389479</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm C.K., et al. Virus&#x2013;cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 2012;13:737&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411909</ArticleId><ArticleId IdType="pubmed">22706339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release. 2015;217:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624045</ArticleId><ArticleId IdType="pubmed">26264835</ArticleId></ArticleIdList></Reference><Reference><Citation>Szebeni J., et al. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nat. Nanotechnol. 2022;17:337&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">35393599</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmers F., et al. The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell. 2021;184:3915&#x2013;3935 e3921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316438</ArticleId><ArticleId IdType="pubmed">34174187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Netea M.G. Trained innate immunity, epigenetics, and Covid-19. N. Engl. J. Med. 2020;383:1078&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">32905684</ArticleId></ArticleIdList></Reference><Reference><Citation>Habibzadeh F., et al. COVID-19 infection among women in Iran exposed vs unexposed to children who received attenuated poliovirus used in oral polio vaccine. JAMA Netw. Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613592</ArticleId><ArticleId IdType="pubmed">34817583</ArticleId></ArticleIdList></Reference><Reference><Citation>Habibzadeh F., et al. Use of oral polio vaccine and the incidence of COVID-19 in the world. PLoS One. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929581</ArticleId><ArticleId IdType="pubmed">35298546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayar E., et al. Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. medRxiv. 2022 doi: 10.1101/2022.05.09.22274802. Published online May 10, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.09.22274802</ArticleId><ArticleId IdType="pmc">PMC9791790</ArticleId><ArticleId IdType="pubmed">36603377</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy D.M., et al. Trained immunity is induced in humans after immunization with an adenoviral vector COVID-19 vaccine. J. Clin. Invest. 2022;2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9843058</ArticleId><ArticleId IdType="pubmed">36282571</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., et al. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 2022;310:6&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry E.J., Barouch D.H. T cell immunity to COVID-19 vaccines. Science. 2022;377:821&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">35981045</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373:eabj0299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449013</ArticleId><ArticleId IdType="pubmed">34529476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman M.J., et al. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Rep. Med. 2021;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8405506</ArticleId><ArticleId IdType="pubmed">34485950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch Y.C., et al. Omicron variant spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci. Transl. Med. 2022;14:eabn9243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995028</ArticleId><ArticleId IdType="pubmed">35289637</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhardt V., et al. Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature. 2021;597:268&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426185</ArticleId><ArticleId IdType="pubmed">34320609</ArticleId></ArticleIdList></Reference><Reference><Citation>Loyal L., et al. Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021;374:eabh1823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10026850</ArticleId><ArticleId IdType="pubmed">34465633</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434&#x2013;2451 e2417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., et al. Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. J. Exp. Med. 2022;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9418484</ArticleId><ArticleId IdType="pubmed">36006380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurme A., et al. Long-lasting T cell responses in BNT162b2 COVID-19 mRNA vaccinees and COVID-19 convalescent patients. Front. Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073085</ArticleId><ArticleId IdType="pubmed">35529867</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 2022;23:186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>GeurtsvanKessel C.H., et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci. Immunol. 2022;7:eabo2202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939771</ArticleId><ArticleId IdType="pubmed">35113647</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi R., et al. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. J. Clin. Invest. 2021;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203458</ArticleId><ArticleId IdType="pubmed">33956667</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 2021;384:1372&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008743</ArticleId><ArticleId IdType="pubmed">33691060</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieman M., et al. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine. 2021;68</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149267</ArticleId><ArticleId IdType="pubmed">34051441</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D.A., et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., et al. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci. Alliance. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8860093</ArticleId><ArticleId IdType="pubmed">35169017</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati C., et al. COVID-19 vaccination in fragile patients: current evidence and an harmonized transdisease trial. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8383886</ArticleId><ArticleId IdType="pubmed">34447374</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Cosimo S., et al. Safety of third dose of COVID-19 vaccination in frail patients: results from the prospective Italian VAX4FRAIL study. Front. Oncol. 2022;12:1002168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9631315</ArticleId><ArticleId IdType="pubmed">36338743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentzer A.J., et al. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat. Med. 2022 doi: 10.1038/s41591-022-02078-6. Published online October 13, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02078-6</ArticleId><ArticleId IdType="pmc">PMC9873562</ArticleId><ArticleId IdType="pubmed">36228659</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltgen K., et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025&#x2013;1040 e1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds C.J., et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377:eabq1841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossler A., et al. Neutralization profile after recovery from SARS-CoV-2 Omicron infection. N. Engl. J. Med. 2022;386:1764&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006769</ArticleId><ArticleId IdType="pubmed">35320661</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S.I., et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022;30:880&#x2013;886 e884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947963</ArticleId><ArticleId IdType="pubmed">35436444</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., et al. Immune imprinting and protection against repeat reinfection with SARS-CoV-2. N. Engl. J. Med. 2022;387:1716&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9634858</ArticleId><ArticleId IdType="pubmed">36223534</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Ibarguengoitia M.E., et al. Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries. Front. Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9367469</ArticleId><ArticleId IdType="pubmed">35967368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchini F., et al. Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2. bioRxiv. 2022 doi: 10.1101/2022.11.24.515932. Published online November 28, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.24.515932</ArticleId><ArticleId IdType="pmc">PMC9972897</ArticleId><ArticleId IdType="pubmed">36701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Macpherson A.J., et al. The immune geography of IgA induction and function. Mucosal Immunol. 2008;1:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19079156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti A., Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28:740&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057455</ArticleId><ArticleId IdType="pubmed">18549797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnewski A.V., et al. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS One. 2021;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8208542</ArticleId><ArticleId IdType="pubmed">34133415</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzi L., et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2022;75</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8718969</ArticleId><ArticleId IdType="pubmed">34954658</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwich A., et al. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? EMBO Mol. Med. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9081904</ArticleId><ArticleId IdType="pubmed">35393790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano K., et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nat. Commun. 2022;13:5135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9435409</ArticleId><ArticleId IdType="pubmed">36050304</ArticleId></ArticleIdList></Reference><Reference><Citation>Alu A., et al. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine. 2022;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8785603</ArticleId><ArticleId IdType="pubmed">35085851</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K., et al. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum. Vaccines Immunother. 2022;18:2045853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935456</ArticleId><ArticleId IdType="pubmed">35258416</ArticleId></ArticleIdList></Reference><Reference><Citation>Afkhami S., et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896&#x2013;915 e819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825346</ArticleId><ArticleId IdType="pubmed">35180381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J., et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci. Immunol. 2022;7:eadd4853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348751</ArticleId><ArticleId IdType="pubmed">35857583</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao T., et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science. 2022;378:eabo2523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9798903</ArticleId><ArticleId IdType="pubmed">36302057</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhavan M., et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. EBioMedicine. 2022;85</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9550199</ArticleId><ArticleId IdType="pubmed">36229342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayenigbara I.O., et al. The challenges to a successful COVID-19 vaccination programme in Africa. Germs. 2021;11:427&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548036</ArticleId><ArticleId IdType="pubmed">34722365</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme W., et al. COVID-19 and microbiome diversity in sub-Saharan Africa. Lancet. 2022;400:429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352272</ArticleId><ArticleId IdType="pubmed">35934003</ArticleId></ArticleIdList></Reference><Reference><Citation>Usuf E., Roca A. Seroprevalence surveys in sub-Saharan Africa: what do they tell us? Lancet Glob. Health. 2021;9:e724&#x2013;e725.</Citation><ArticleIdList><ArticleId IdType="pubmed">33711261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis H.C., et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob. Health. 2022;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402450</ArticleId><ArticleId IdType="pubmed">35998978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawal L., et al. Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward. Hum. Vaccin. Immunother. 2022;18:2034457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9009957</ArticleId><ArticleId IdType="pubmed">35240908</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A.T., et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob. Health. 2022;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9136695</ArticleId><ArticleId IdType="pubmed">35618305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwananyanda L., et al. Covid-19 deaths in Africa: prospective systematic postmortem surveillance study. BMJ. 2021;372</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887952</ArticleId><ArticleId IdType="pubmed">33597166</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . 2022. Protect the promise: 2022 progress report on the Every Woman Every Child Global Strategy for Women&#x2019;s, Children&#x2019;s and Adolescents&#x2019; Health (2016&#x2013;2030). Geneva: World Health Organization and the United Nations Children&#x2019;s Fund (UNICEF), 2022. Licence: CC BY-NC-SA 3.0 IGO.</Citation></Reference><Reference><Citation>Soy A.  BBC News; 2021. Africa&#x2019;s long wait for the Covid-19 vaccine.https://www.bbc.com/news/world-africa-55751714 22 January.</Citation></Reference><Reference><Citation>Africa CDC . Africa CDC; 2022. COVID-19 vaccination.https://africacdc.org/covid-19-vaccination/</Citation></Reference><Reference><Citation>Tegally H., et al. The evolving SARS-CoV-2 epidemic in Africa: insights from rapidly expanding genomic surveillance. Science. 2022;378:eabq5358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9529057</ArticleId><ArticleId IdType="pubmed">36108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., et al. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022;28:1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., et al. Association between vaccination with BNT162b2 vaccine and Long COVID after infections not requiring hospitalization in healthcare workers. JAMA. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P., et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. npj Vaccines. 2022;7:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>McMenamin M.E., et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect. Dis. 2022;22:1435&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286709</ArticleId><ArticleId IdType="pubmed">35850128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182:713&#x2013;721 e719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275151</ArticleId><ArticleId IdType="pubmed">32778225</ArticleId></ArticleIdList></Reference><Reference><Citation>Longhua Government Online . Shenzhen Daily; 2021. Indigenous COVID-19 vaccine put into use in city.www.szlhq.gov.cn/english/epidemic_prevention/news2020/content/post_8820257.html</Citation></Reference><Reference><Citation>Li J.X., Zhu F.C. Adjuvantation helps to optimise COVID-19 vaccine candidate. Lancet Infect. Dis. 2021;21:891&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221731</ArticleId><ArticleId IdType="pubmed">33705726</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz E. China and India approve nasal COVID vaccines &#x2014; are they a game changer? Nature. 2022;609:450.</Citation><ArticleIdList><ArticleId IdType="pubmed">36071228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi S., et al. Development of inactivated FAKHRAVAC((R)) vaccine against SARS-CoV-2 virus: preclinical study in animal models. Vaccines (Basel) 2021;9:1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8622747</ArticleId><ArticleId IdType="pubmed">34835202</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi M., et al. Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern. Clin. Microbiol. Infect. 2022;28:882.e1&#x2013;882.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893932</ArticleId><ArticleId IdType="pubmed">35248745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakarya K., et al. Safety and immunogenicity of a QazCovid-in(R) inactivated whole-virion vaccine against COVID-19 in healthy adults: a single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine. 2021;39</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363482</ArticleId><ArticleId IdType="pubmed">34414368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishmukhametov A.A., et al. Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial. medRxiv. 2022 doi: 10.1101/2022.02.08.22270658. Published online February 9, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.08.22270658</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Institutes of Turkey . 2021. Efficacy, immunogenicity, and safety of the inactivated COVID-19 vaccine (TURKOVAC) versus the CoronaVac vaccine. ClinicalTrials.gov; 24/06/2021; TrialID: NCT04942405.</Citation></Reference><Reference><Citation>Lazarus R., et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect. Dis. 2022;22:1716&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9444237</ArticleId><ArticleId IdType="pubmed">36075233</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabarsi P., et al. Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. Clin. Microbiol. Infect. 2022 doi: 10.1016/j.cmi.2022.09.001. Published online September 10, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9463077</ArticleId><ArticleId IdType="pubmed">36096430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hager K.J., et al. Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine. N. Engl. J. Med. 2022;386:2084&#x2013;2096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127773</ArticleId><ArticleId IdType="pubmed">35507508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaabi N.A., et al. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal. Transduct. Target Ther. 2022;7:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9167817</ArticleId><ArticleId IdType="pubmed">35665745</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov A phase III clinical trial to determine the safety and efficacy of ZF2001 for prevention of COVID-19. 2022. https://clinicaltrials.gov/ct2/show/NCT04646590#wrapper</Citation></Reference><Reference><Citation>Mas-Bermejo P.I., et al. Cuban Abdala vaccine: effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; a cohort study. Lancet Reg. Health Am. 2022;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9507841</ArticleId><ArticleId IdType="pubmed">36185968</ArticleId></ArticleIdList></Reference><Reference><Citation>Eugenia-Toledo-Romani M., et al. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: open label phase I and phase IIa clinical trials. Vaccine. 2022;40:4220&#x2013;4230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9167831</ArticleId><ArticleId IdType="pubmed">35691871</ArticleId></ArticleIdList></Reference><Reference><Citation>Puga-G&#xf3;mez R., et al. Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children. medRxiv. 2022 doi: 10.1101/2022.03.03.22271313. Published online March 18, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.03.22271313</ArticleId></ArticleIdList></Reference><Reference><Citation>Iranian Registry of Clinical Trials Phase II, safety and immunogenicity of RAZI SARS-CoV-2 recombinant spike protein vaccine (RAZI Cov Pars) in adults aged 18&#x2013;70 years; a randomised, double-blind, parallel 2 arms clinical trial. 2022. https://en.irct.ir/trial/55238</Citation></Reference><Reference><Citation>Sizyakina L.P., et al. Post-vaccination immunity phenotypes upon usage of EpiVacCorona vaccine in the persons who suffered COVID-19. Med. Immunol. (Russia) 2022;24:367&#x2013;378.</Citation></Reference><Reference><Citation>Waits A., et al. Safety and immunogenicity of MVC-COV1901 vaccine in older adults: phase 2 randomized dose-comparison trial. Int. J. Infect. Dis. 2022;124:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9422336</ArticleId><ArticleId IdType="pubmed">36049700</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuluva S., et al. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine. 2022;83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9372721</ArticleId><ArticleId IdType="pubmed">35970020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallory R.M., et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 2022;22:1565&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365313</ArticleId><ArticleId IdType="pubmed">35963274</ArticleId></ArticleIdList></Reference><Reference><Citation>Khobragade A., et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399:1313&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8970574</ArticleId><ArticleId IdType="pubmed">35367003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P., et al. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial. PLoS Med. 2022;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187065</ArticleId><ArticleId IdType="pubmed">35617368</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti P.M., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsundue T., et al. First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India. BMJ Glob. Health. 2022;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9130647</ArticleId><ArticleId IdType="pubmed">35609920</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov D.Y., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukhvatulin A.I., et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine &#x2018;Sputnik Light&#x2019; for prevention of coronavirus infection in healthy adults. Lancet Reg. Health Eur. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8562788</ArticleId><ArticleId IdType="pubmed">34746910</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston E.H., et al. The Johnson &amp; Johnson vaccine for COVID-19. JAMA. 2021;325:1575.</Citation><ArticleIdList><ArticleId IdType="pubmed">33646285</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer and BioNTech Pfizer and BioNTech receive positive CHMP opinion for Omicron BA-1-adapted bivalent COVID-19 vaccine booster in European Union. PfizerBioNTech. 2022 www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron</Citation></Reference><Reference><Citation>Pfizer and BioNTech . PfizerBioNTech; 2022. Pfizer and BioNTech announce updated clinical data for Omicron BA.4/BA.5-adapted bivalent booster demonstrating substantially higher immune response in adults compared to the original COVID-19 vaccine.www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron</Citation></Reference><Reference><Citation>Baden L.R., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 2022;387:1279&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderna . Moderna; 2022. European Medicines Agency accepts Moderna&#x2019;s conditional marketing authorization filing for its Omicron BA.4/BA.5 targeting bivalent COVID-19 vaccine.https://investors.modernatx.com/news/news-details/2022/European-Medicines-Agency-Accepts-Modernas-Conditional-Marketing-Authorization-Filing-for-its-Omicron-BA.4BA.5-Targeting-Bivalent-COVID-19-Vaccine/default.aspx</Citation></Reference><Reference><Citation>Sanofi . Sanofi; 2022. Sanofi and GSK&#x2019;s next-generation COVID-19 booster vaccine.https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-10-15-36-50-2553486</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>